273 related articles for article (PubMed ID: 21669382)
1. A meta-analysis of osteoporotic fracture risk with medication nonadherence.
Ross S; Samuels E; Gairy K; Iqbal S; Badamgarav E; Siris E
Value Health; 2011 Jun; 14(4):571-81. PubMed ID: 21669382
[TBL] [Abstract][Full Text] [Related]
2. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures .
Meijer WM; Penning-van Beest FJ; Olson M; Herings RM
Curr Med Res Opin; 2008 Nov; 24(11):3217-22. PubMed ID: 18922215
[TBL] [Abstract][Full Text] [Related]
3. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China.
Wang X; Li C; He Y; Wang T; Zhang H; Ma Z; Ma H; Zhao H
Arch Osteoporos; 2020 Aug; 15(1):134. PubMed ID: 32820451
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of osteoporosis: fracture risks, medication and treatment.
Liu W; Yang LH; Kong XC; An LK; Wang R
Minerva Med; 2015 Aug; 106(4):203-14. PubMed ID: 26125152
[TBL] [Abstract][Full Text] [Related]
5. Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence.
Sampalis JS; Adachi JD; Rampakakis E; Vaillancourt J; Karellis A; Kindundu C
J Bone Miner Res; 2012 Jan; 27(1):202-10. PubMed ID: 21976304
[TBL] [Abstract][Full Text] [Related]
6. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study.
van den Boogaard CH; Breekveldt-Postma NS; Borggreve SE; Goettsch WG; Herings RM
Curr Med Res Opin; 2006 Sep; 22(9):1757-64. PubMed ID: 16968579
[TBL] [Abstract][Full Text] [Related]
7. The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.
Hiligsmann M; Boonen A; Rabenda V; Reginster JY
Expert Rev Pharmacoecon Outcomes Res; 2012 Apr; 12(2):159-66. PubMed ID: 22458617
[TBL] [Abstract][Full Text] [Related]
8. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
9. The impact of thyroid diseases on bone metabolism and fracture risk.
Amashukeli M; Giorgadze E; Tsagareli M; Nozadze N; Jeiranashvili N
Georgian Med News; 2010; (184-185):34-9. PubMed ID: 20834073
[TBL] [Abstract][Full Text] [Related]
10. Impact of bisphosphonate compliance on the risk of osteoporotic fracture in France.
Belhassen M; Cortet B; Confavreux CB; Lamezec L; Ginoux M; Van Ganse E
Arch Osteoporos; 2018 Oct; 13(1):113. PubMed ID: 30341636
[TBL] [Abstract][Full Text] [Related]
11. Osteoporosis: is there a rational approach to fracture prevention?
Lane N
Bull NYU Hosp Jt Dis; 2006; 64(1-2):67-71. PubMed ID: 17121493
[TBL] [Abstract][Full Text] [Related]
12. The economics of fragility fractures in West Virginia.
Pfister AK; Sale WG; Shaukat S
W V Med J; 2009; 105(4):10-3. PubMed ID: 19585898
[TBL] [Abstract][Full Text] [Related]
13. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
14. Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture.
Perreault S; Dragomir A; Blais L; Moride Y; Rossignol M; Ste-Marie LG; Fernandès JC
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):248-59. PubMed ID: 18213734
[TBL] [Abstract][Full Text] [Related]
15. The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany.
Hadji P; Klein S; Häussler B; Kless T; Linder R; Rowinski-Jablokow M; Verheyen F; Gothe H
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):868-72. PubMed ID: 24040854
[TBL] [Abstract][Full Text] [Related]
16. Compliance with drug therapies for the treatment and prevention of osteoporosis.
McCombs JS; Thiebaud P; McLaughlin-Miley C; Shi J
Maturitas; 2004 Jul; 48(3):271-87. PubMed ID: 15207894
[TBL] [Abstract][Full Text] [Related]
17. Proportion of osteoporotic women remaining at risk for fracture despite adherence to oral bisphosphonates.
Imel EA; Eckert G; Modi A; Li Z; Martin J; de Papp A; Allen K; Johnston CC; Hui SL; Liu Z
Bone; 2016 Feb; 83():267-275. PubMed ID: 26657827
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology, etiology, and diagnosis of osteoporosis.
Lane NE
Am J Obstet Gynecol; 2006 Feb; 194(2 Suppl):S3-11. PubMed ID: 16448873
[TBL] [Abstract][Full Text] [Related]
19. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
Adami S; Isaia G; Luisetto G; Minisola S; Sinigaglia L; Gentilella R; Agnusdei D; Iori N; Nuti R;
J Bone Miner Res; 2006 Oct; 21(10):1565-70. PubMed ID: 16995811
[TBL] [Abstract][Full Text] [Related]
20. Overcoming problems with adherence to osteoporosis medication.
Rabenda V; Reginster JY
Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):677-89. PubMed ID: 21155701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
